NEKTAR THERAPEUTICS (NKTR) Stock Price, Quote, News and Overview
NASDAQ:NKTR - Nasdaq - US6402681083 - Common Stock - Currency: USD
NKTR Quote, Performance and Key Statistics
0.9322
-0.02 (-2.58%)
The current stock price of NKTR is 0.9322 USD. In the past month the price increased by 4.2%. In the past year, price increased by 36.61%.
NKTR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About NKTR
Company Profile
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 137 full-time employees. The firm is focused on discovering and developing medicines in the field of immunotherapy. The firm has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
Company Info
NEKTAR THERAPEUTICS
455 Mission Bay Boulevard South
San Francisco CALIFORNIA 94158 US
CEO: Howard W. Robin
Employees: 137
Company Website: https://www.nektar.com/
Investor Relations: https://ir.nektar.com/
Phone: 18554826587
NEKTAR THERAPEUTICS / NKTR FAQ
What is the stock price of NEKTAR THERAPEUTICS today?
The current stock price of NKTR is 0.9322 USD. The price decreased by -2.58% in the last trading session.
What is the ticker symbol for NEKTAR THERAPEUTICS stock?
The exchange symbol of NEKTAR THERAPEUTICS is NKTR and it is listed on the Nasdaq exchange.
On which exchange is NKTR stock listed?
NKTR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEKTAR THERAPEUTICS stock?
14 analysts have analysed NKTR and the average price target is 4.65 USD. This implies a price increase of 398.95% is expected in the next year compared to the current price of 0.9322. Check the NEKTAR THERAPEUTICS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEKTAR THERAPEUTICS worth?
NEKTAR THERAPEUTICS (NKTR) has a market capitalization of 171.95M USD. This makes NKTR a Micro Cap stock.
How many employees does NEKTAR THERAPEUTICS have?
NEKTAR THERAPEUTICS (NKTR) currently has 137 employees.
What are the support and resistance levels for NEKTAR THERAPEUTICS (NKTR) stock?
NEKTAR THERAPEUTICS (NKTR) has a support level at 0.92 and a resistance level at 0.99. Check the full technical report for a detailed analysis of NKTR support and resistance levels.
Is NEKTAR THERAPEUTICS (NKTR) expected to grow?
The Revenue of NEKTAR THERAPEUTICS (NKTR) is expected to grow by 17.72% in the next year. Check the estimates tab for more information on the NKTR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEKTAR THERAPEUTICS (NKTR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NKTR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NKTR, evaluating the profitability, health, valuation and growth aspects
- NEKTAR THERAPEUTICS (NKTR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEKTAR THERAPEUTICS (NKTR) Sales and EPS estimates to see what analysts future expectations are.
- NEKTAR THERAPEUTICS (NKTR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEKTAR THERAPEUTICS (NKTR) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEKTAR THERAPEUTICS (NKTR) Stock Chart to make your own analysis
- NEKTAR THERAPEUTICS (NKTR) Latest news and press-releases to stay up to date.
Does NEKTAR THERAPEUTICS (NKTR) stock pay dividends?
NKTR does not pay a dividend.
When does NEKTAR THERAPEUTICS (NKTR) report earnings?
NEKTAR THERAPEUTICS (NKTR) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of NEKTAR THERAPEUTICS (NKTR)?
NEKTAR THERAPEUTICS (NKTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.84).
What is the Short Interest ratio of NEKTAR THERAPEUTICS (NKTR) stock?
The outstanding short interest for NEKTAR THERAPEUTICS (NKTR) is 3.16% of its float. Check the ownership tab for more information on the NKTR short interest.
NKTR Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NKTR. When comparing the yearly performance of all stocks, NKTR is one of the better performing stocks in the market, outperforming 79.87% of all stocks.
NKTR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NKTR. The financial health of NKTR is average, but there are quite some concerns on its profitability.
NKTR Financial Highlights
Over the last trailing twelve months NKTR reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 26.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.65% | ||
| ROE | -344.29% | ||
| Debt/Equity | 0 |
NKTR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to NKTR. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 25.48% and a revenue growth 17.72% for NKTR